Structural and Biochemical Characterization of in Vivo Assembled Lactococcus Lactis CRISPR-Csm Complex

Overview

Journal Commun Biol

Specialty Biology

Date 2022 Mar 30

PMID 35351985

Authors

Sagar Sridhara

Jay Rai

Charlisa Whyms

Hemant Goswami

Huan He

Walter Woodside

Michael P Terns

Hong Li

Affiliations

Soon will be listed here.

Abstract

The small RNA-mediated immunity in bacteria depends on foreign RNA-activated and self RNA-inhibited enzymatic activities. The multi-subunit Type III-A CRISPR-Cas effector complex (Csm) exemplifies this principle and is in addition regulated by cellular metabolites such as divalent metals and ATP. Recognition of the foreign or cognate target RNA (CTR) triggers its single-stranded deoxyribonuclease (DNase) and cyclic oligoadenylate (cOA) synthesis activities. The same activities remain dormant in the presence of the self or non-cognate target RNA (NTR) that differs from CTR only in its 3'-protospacer flanking sequence (3'-PFS). Here we employ electron cryomicroscopy (cryoEM), functional assays, and comparative cross-linking to study in vivo assembled mesophilic Lactococcus lactis Csm (LlCsm) at the three functional states: apo, the CTR- and the NTR-bound. Unlike previously studied Csm complexes, we observed binding of 3'-PFS to Csm in absence of bound ATP and analyzed the structures of the four RNA cleavage sites. Interestingly, comparative crosslinking results indicate a tightening of the Csm3-Csm4 interface as a result of CTR but not NTR binding, reflecting a possible role of protein dynamics change during activation.

Citing Articles

Mechanistic determinants and dynamics of cA6 synthesis in type III CRISPR-Cas effector complexes.

Jungfer K, Moravcik S, Garcia-Doval C, Knorlein A, Hall J, Jinek M Nucleic Acids Res. 2025; 53(2).

PMID: 39817514 PMC: 11734703. DOI: 10.1093/nar/gkae1277.

Selective degradation of phage RNAs by the Csm6 ribonuclease provides robust type III CRISPR immunity in Streptococcus thermophilus.

Johnson K, Garrett S, Noble-Molnar C, Elgarhi H, Woodside W, Cooper C Nucleic Acids Res. 2024; 52(20):12549-12564.

PMID: 39360614 PMC: 11551762. DOI: 10.1093/nar/gkae856.

Molecular basis for cA6 synthesis by a type III-A CRISPR-Cas enzyme and its conversion to cA4 production.

Goswami H, Ahmadizadeh F, Wang B, Addo-Yobo D, Zhao Y, Whittington A Nucleic Acids Res. 2024; 52(17):10619-10629.

PMID: 38989619 PMC: 11417356. DOI: 10.1093/nar/gkae603.

RNA targeting and cleavage by the type III-Dv CRISPR effector complex.

Schwartz E, Bravo J, Ahsan M, Macias L, McCafferty C, Dangerfield T Nat Commun. 2024; 15(1):3324.

PMID: 38637512 PMC: 11026444. DOI: 10.1038/s41467-024-47506-y.

The structure of a Type III-A CRISPR-Cas effector complex reveals conserved and idiosyncratic contacts to target RNA and crRNA among Type III-A systems.

Paraan M, Nasef M, Chou-Zheng L, Khweis S, Schoeffler A, Hatoum-Aslan A PLoS One. 2023; 18(6):e0287461.

PMID: 37352230 PMC: 10289348. DOI: 10.1371/journal.pone.0287461.

References

Sherwood A, Henkin T . Riboswitch-Mediated Gene Regulation: Novel RNA Architectures Dictate Gene Expression Responses. Annu Rev Microbiol. 2016; 70:361-74. DOI: 10.1146/annurev-micro-091014-104306. View

Marraffini L, Sontheimer E . CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nat Rev Genet. 2010; 11(3):181-90. PMC: 2928866. DOI: 10.1038/nrg2749. View

Koonin E, Makarova K, Zhang F . Diversity, classification and evolution of CRISPR-Cas systems. Curr Opin Microbiol. 2017; 37:67-78. PMC: 5776717. DOI: 10.1016/j.mib.2017.05.008. View

Wright A, Nunez J, Doudna J . Biology and Applications of CRISPR Systems: Harnessing Nature's Toolbox for Genome Engineering. Cell. 2016; 164(1-2):29-44. DOI: 10.1016/j.cell.2015.12.035. View

Mohanraju P, Makarova K, Zetsche B, Zhang F, Koonin E, van der Oost J . Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems. Science. 2016; 353(6299):aad5147. DOI: 10.1126/science.aad5147. View

Makarova K, Wolf Y, Alkhnbashi O, Costa F, Shah S, Saunders S . An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol. 2015; 13(11):722-36. PMC: 5426118. DOI: 10.1038/nrmicro3569. View

Goldberg G, Jiang W, Bikard D, Marraffini L . Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting. Nature. 2014; 514(7524):633-7. PMC: 4214910. DOI: 10.1038/nature13637. View

Kazlauskiene M, Kostiuk G, Venclovas C, Tamulaitis G, Siksnys V . A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems. Science. 2017; 357(6351):605-609. DOI: 10.1126/science.aao0100. View

Niewoehner O, Garcia-Doval C, Rostol J, Berk C, Schwede F, Bigler L . Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers. Nature. 2017; 548(7669):543-548. DOI: 10.1038/nature23467. View

10.

Mo C, Mathai J, Rostol J, Varble A, Banh D, Marraffini L . Type III-A CRISPR immunity promotes mutagenesis of staphylococci. Nature. 2021; 592(7855):611-615. PMC: 8820005. DOI: 10.1038/s41586-021-03440-3. View

11.

Santiago-Frangos A, Hall L, Nemudraia A, Nemudryi A, Krishna P, Wiegand T . Intrinsic signal amplification by type III CRISPR-Cas systems provides a sequence-specific SARS-CoV-2 diagnostic. Cell Rep Med. 2021; 2(6):100319. PMC: 8157118. DOI: 10.1016/j.xcrm.2021.100319. View

12.

Sridhara S, Goswami H, Whyms C, Dennis J, Li H . Virus detection via programmable Type III-A CRISPR-Cas systems. Nat Commun. 2021; 12(1):5653. PMC: 8476571. DOI: 10.1038/s41467-021-25977-7. View

13.

Steens J, Zhu Y, Taylor D, Bravo J, Prinsen S, Schoen C . SCOPE enables type III CRISPR-Cas diagnostics using flexible targeting and stringent CARF ribonuclease activation. Nat Commun. 2021; 12(1):5033. PMC: 8376896. DOI: 10.1038/s41467-021-25337-5. View

14.

Kazlauskiene M, Tamulaitis G, Kostiuk G, Venclovas C, Siksnys V . Spatiotemporal Control of Type III-A CRISPR-Cas Immunity: Coupling DNA Degradation with the Target RNA Recognition. Mol Cell. 2016; 62(2):295-306. DOI: 10.1016/j.molcel.2016.03.024. View

15.

Ichikawa H, Cooper J, Lo L, Potter J, Terns R, Terns M . Programmable type III-A CRISPR-Cas DNA targeting modules. PLoS One. 2017; 12(4):e0176221. PMC: 5404769. DOI: 10.1371/journal.pone.0176221. View

16.

Samai P, Pyenson N, Jiang W, Goldberg G, Hatoum-Aslan A, Marraffini L . Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity. Cell. 2015; 161(5):1164-1174. PMC: 4594840. DOI: 10.1016/j.cell.2015.04.027. View

17.

Tamulaitis G, Kazlauskiene M, Manakova E, Venclovas C, Nwokeoji A, Dickman M . Programmable RNA shredding by the type III-A CRISPR-Cas system of Streptococcus thermophilus. Mol Cell. 2014; 56(4):506-17. DOI: 10.1016/j.molcel.2014.09.027. View

18.

Staals R, Zhu Y, Taylor D, Kornfeld J, Sharma K, Barendregt A . RNA targeting by the type III-A CRISPR-Cas Csm complex of Thermus thermophilus. Mol Cell. 2014; 56(4):518-30. PMC: 4342149. DOI: 10.1016/j.molcel.2014.10.005. View

19.

Marraffini L, Sontheimer E . Self versus non-self discrimination during CRISPR RNA-directed immunity. Nature. 2010; 463(7280):568-71. PMC: 2813891. DOI: 10.1038/nature08703. View

20.

Ramia N, Tang L, Cocozaki A, Li H . Staphylococcus epidermidis Csm1 is a 3'-5' exonuclease. Nucleic Acids Res. 2013; 42(2):1129-38. PMC: 3902914. DOI: 10.1093/nar/gkt914. View